Assenagon Asset Management S.A. cut its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 66.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 143,806 shares of the biotechnology company's stock after selling 282,755 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.68% of Enanta Pharmaceuticals worth $1,490,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in ENTA. State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals in the first quarter valued at $118,000. Vanguard Group Inc. lifted its position in Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock worth $33,664,000 after acquiring an additional 134,292 shares during the period. Acadian Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company's stock valued at $14,906,000 after purchasing an additional 10,952 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter worth approximately $191,000. Finally, Farallon Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company's stock worth $36,579,000 after purchasing an additional 70,000 shares during the period. Hedge funds and other institutional investors own 94.99% of the company's stock.
Enanta Pharmaceuticals Stock Performance
ENTA stock traded down $0.29 during midday trading on Friday, hitting $10.95. 100,080 shares of the stock were exchanged, compared to its average volume of 201,727. The stock's 50-day moving average price is $11.73 and its 200-day moving average price is $12.72. The stock has a market cap of $232.03 million, a price-to-earnings ratio of -2.01 and a beta of 0.58. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $8.08 and a fifty-two week high of $17.80.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The business had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. The business's revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.27) EPS. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current year.
Analysts Set New Price Targets
ENTA has been the subject of several recent analyst reports. JMP Securities restated a "market outperform" rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating on the stock in a report on Tuesday, August 6th. Finally, Evercore ISI upgraded shares of Enanta Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $20.00.
Check Out Our Latest Research Report on Enanta Pharmaceuticals
About Enanta Pharmaceuticals
(
Free Report)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
See Also
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
